Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.

Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J, Sudworth M, Cater NB, Breazna A, Oldgren J, Kirchhof P.

Eur Heart J. 2018 Apr 6. doi: 10.1093/eurheartj/ehy148. [Epub ahead of print]

PMID:
29659797
2.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia.

Langslet G, Breazna A, Drogari E.

J Clin Lipidol. 2016 Sep-Oct;10(5):1153-1162.e3. doi: 10.1016/j.jacl.2016.05.010. Epub 2016 Jun 7.

3.

Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.

Ezekowitz MD, Pollack CV, Sanders P, Halperin JL, Spahr J, Cater N, Petkun W, Breazna A, Kirchhof P, Oldgren J.

Am Heart J. 2016 Sep;179:59-68. doi: 10.1016/j.ahj.2016.06.008. Epub 2016 Jun 19.

4.

Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes.

Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators.

Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30.

PMID:
27513651
5.

Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study).

Shepherd J, Breazna A, Deedwania PC, LaRosa JC, Wenger NK, Messig M, Wilson DJ; Treating to New Targets Steering Committee and Investigators.

Am J Cardiol. 2016 Apr 15;117(8):1199-205. doi: 10.1016/j.amjcard.2016.01.014. Epub 2016 Jan 28.

6.

A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.

Bruce JY, LoRusso PM, Goncalves PH, Heath EI, Sadowski E, Shalinsky DR, Zhang Y, Traynor AM, Breazna A, Ricart AD, Tortorici M, Liu G.

Cancer Chemother Pharmacol. 2016 Mar;77(3):527-38. doi: 10.1007/s00280-016-2958-1. Epub 2016 Jan 20.

PMID:
26791870
7.

Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study.

Deedwania PC, Shepherd J, Breazna A, DeMicco DA; Treating to New Targets (TNT) Steering Committee Investigators.

Diabetes Obes Metab. 2016 Jan;18(1):56-63. doi: 10.1111/dom.12581.

PMID:
26434404
8.

Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.

Bangalore S, Breazna A, DeMicco DA, Wun CC, Messerli FH; TNT Steering Committee and Investigators.

J Am Coll Cardiol. 2015 Apr 21;65(15):1539-48. doi: 10.1016/j.jacc.2015.02.017.

9.

Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.

Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, Motzer RJ.

Eur J Cancer. 2014 Aug;50(12):2162-70. doi: 10.1016/j.ejca.2014.05.013. Epub 2014 Jun 12.

PMID:
24930624
10.

Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.

Grill J, Geoerger B, Gesner L, Perek D, Leblond P, Cañete A, Aerts I, Madero L, de Toledo Codina JS, Verlooy J, Estlin E, Cisar L, Breazna A, Dorman A, Bailey S, Nicolin G, Grundy RG, Hargrave D; European Consortium Innovative Therapies for Children with Cancer (ITCC) and the European Society for Paediatric Oncology (SIOPE) brain tumor group.

Neuro Oncol. 2013 Sep;15(9):1236-43. doi: 10.1093/neuonc/not097. Epub 2013 Jul 14.

11.

A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.

Hargrave D, Geoerger B, Frappaz D, Pietsch T, Gesner L, Cisar L, Breazna A, Dorman A, Cruz-Martinez O, Fuster JL, Rialland X, Icher C, Leblond P, Ashley D, Perilongo G, Elliott M, English M, Clausen N, Grill J.

J Neurooncol. 2013 May;113(1):127-34. doi: 10.1007/s11060-013-1098-2. Epub 2013 Mar 4.

PMID:
23459995
12.

Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.

Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, Breazna A, Pedersen TR.

J Am Coll Cardiol. 2013 Jan 15;61(2):148-52. doi: 10.1016/j.jacc.2012.09.042. Epub 2012 Dec 5. Erratum in: J Am Coll Cardiol. 2014 Nov 4;64(18):1970.

13.

Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.

Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD.

Circulation. 2012 Apr 24;125(16):1979-87. doi: 10.1161/CIRCULATIONAHA.111.088591. Epub 2012 Mar 29.

14.

Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).

Ho JE, Waters DD, Kean A, Wilson DJ, Demicco DA, Breazna A, Wun CC, Deedwania PC, Khush KK; TNT Investigators.

Am J Cardiol. 2012 Jun 15;109(12):1761-6. doi: 10.1016/j.amjcard.2012.02.019. Epub 2012 Mar 28.

15.

Treatment of osteoarthritis with continuous versus intermittent celecoxib.

Strand V, Simon LS, Dougados M, Sands GH, Bhadra P, Breazna A, Immitt J.

J Rheumatol. 2011 Dec;38(12):2625-34. doi: 10.3899/jrheum.110636. Epub 2011 Nov 1.

PMID:
22045833
16.

Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, Kastelein JJ.

Circulation. 2011 Aug 2;124(5):555-62. doi: 10.1161/CIRCULATIONAHA.111.018259. Epub 2011 Jul 18.

PMID:
21804130
17.

Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial.

Arber N, Spicak J, Rácz I, Zavoral M, Breazna A, Gerletti P, Lechuga MJ, Collins N, Rosenstein RB, Eagle CJ, Levin B.

Am J Gastroenterol. 2011 Jun;106(6):1135-46. doi: 10.1038/ajg.2011.116. Epub 2011 Apr 19.

PMID:
21503000
18.

Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials.

Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, Kastelein JJ, Colhoun H, Barter P.

J Am Coll Cardiol. 2011 Apr 5;57(14):1535-45. doi: 10.1016/j.jacc.2010.10.047.

19.

Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials).

Frey P, Waters DD, DeMicco DA, Breazna A, Samuels L, Pipe A, Wun CC, Benowitz NL.

Am J Cardiol. 2011 Jan 15;107(2):145-50. doi: 10.1016/j.amjcard.2010.09.006. Epub 2010 Dec 2.

PMID:
21129718
20.
21.

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.

Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A; LEADe Investigators.

Neurology. 2010 Mar 23;74(12):956-64. doi: 10.1212/WNL.0b013e3181d6476a. Epub 2010 Mar 3.

PMID:
20200346
22.

Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial).

LaRosa JC, Deedwania PC, Shepherd J, Wenger NK, Greten H, DeMicco DA, Breazna A; TNT Investigators.

Am J Cardiol. 2010 Feb 1;105(3):283-7. doi: 10.1016/j.amjcard.2009.09.025. Epub 2009 Dec 22.

PMID:
20102935
23.

A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract.

Chan FK, Cryer B, Goldstein JL, Lanas A, Peura DA, Scheiman JM, Simon LS, Singh G, Stillman MJ, Wilcox CM, Berger MF, Breazna A, Dodge W.

J Rheumatol. 2010 Jan;37(1):167-74. doi: 10.3899/jrheum.090168. Epub 2009 Nov 2.

PMID:
19884267
24.

Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET; Adenoma Prevention with Celecoxib Study Investigators.

Cancer Prev Res (Phila). 2009 Apr;2(4):310-21. doi: 10.1158/1940-6207.CAPR-08-0206. Epub 2009 Mar 31.

25.

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, Eagle CJ, Hawk ET, Bertagnolli MM.

Gastroenterology. 2009 Jun;136(7):2127-2136.e1. doi: 10.1053/j.gastro.2009.02.045. Epub 2009 Feb 21.

26.

Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study).

Johnson C, Waters DD, DeMicco DA, Breazna A, Bittner V, Greten H, Grundy SM, LaRosa JC.

Am J Cardiol. 2008 Nov 15;102(10):1312-7. doi: 10.1016/j.amjcard.2008.07.023. Epub 2008 Sep 5.

PMID:
18993147
27.

Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.

Chaturvedi S, Zivin J, Breazna A, Amarenco P, Callahan A, Goldstein LB, Hennerici M, Sillesen H, Rudolph A, Welch MA; SPARCL Investigators.

Neurology. 2009 Feb 24;72(8):688-94. doi: 10.1212/01.wnl.0000327339.55844.1a. Epub 2008 Sep 3.

PMID:
18768917
28.

Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.

Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK; Treating to New Targets Steering Committee and Investigators.

Mayo Clin Proc. 2008 Aug;83(8):870-9.

PMID:
18674471
29.

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.

Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H; LEADe investigators.

Alzheimers Dement. 2008 Mar;4(2):145-53. doi: 10.1016/j.jalz.2008.02.001.

PMID:
18631958
30.

Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.

Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC.

J Am Coll Cardiol. 2008 May 20;51(20):1938-43. doi: 10.1016/j.jacc.2007.12.054.

31.

The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study.

Kostis JB, Breazna A, Deedwania PC, LaRosa JC; Treating to New Targets Steering Committee and Investigators.

J Clin Hypertens (Greenwich). 2008 May;10(5):367-76.

32.

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators.

J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072.

33.

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; Treating to New Targets Investigators.

Clin J Am Soc Nephrol. 2007 Nov;2(6):1131-9. Epub 2007 Oct 17.

34.

Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.

Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM.

J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. Epub 2006 Oct 17.

35.

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.

Diabetes Care. 2006 Jun;29(6):1220-6.

PMID:
16731999
36.

Prenatal and postnatal methylmercury exposure and neurodevelopmental outcomes.

Cox C, Breazna A, Davidson PW, Myers GJ, Clarkson TW.

JAMA. 1999 Oct 13;282(14):1333-4. No abstract available.

PMID:
10527178

Supplemental Content

Loading ...
Support Center